Mycobacterium tuberculosis and nontuberculous mycobacterium (NTM) infections often exhibit similar clinical symptoms. Timely and effective treatment relies on the rapid and accurate identification of species and resistance genotypes. In this study, a new platform (GenSeizer), which combines bioinformatics analysis of a large data set and multiplex PCR-based targeted gene sequencing, was developed to identify 10 major Mycobacterium species that cause pulmonary, as well as extrapulmonary, human diseases. The simultaneous detection of certain erm(41) and rrl resistance genotypes in M. abscessus was also feasible. This platform was specific and sensitive and exhibited no cross-reactivity among reference strains and a detection limit of 5 DNA copies or 50 CFU Mycobacterium/ml. In a blind comparison, GenSeizer and multigene sequencing showed 100% agreement in the ability to identify 88 clinical Mycobacterium isolates. The resistance genotypes, confirmed by whole-genome sequencing of 30 M. abscessus strains, were also correctly identified by GenSeizer 100% of the time. These results indicate that GenSeizer is an efficient, reliable platform for detecting major pathogenic Mycobacterium species.

中文翻译：

---

GenSeizer：基于多重PCR的靶向基因测序平台，用于快速，准确地鉴定主要分枝杆菌种类

结核分枝杆菌和非结核分枝杆菌（NTM）感染通常表现出相似的临床症状。及时有效的治疗取决于对物种和抗性基因型的快速准确识别。在这项研究中，开发了一个新平台（GenSeizer），该平台结合了大数据集的生物信息学分析和基于多重PCR的靶向基因测序，可识别导致肺以及肺外人类疾病的10种主要分枝杆菌。同时检测脓肿中某些erm（41）和rrl抗性基因型也可行。该平台是特异性和灵敏的，在参考菌株之间没有交叉反应，检测限为5个DNA拷贝或50 CFU分枝杆菌/ ml。在盲目比较中，GenSeizer和多基因测序在鉴定88种临床分枝杆菌菌株的能力上显示出100％的一致性。GenSeizer还可以在100％的时间内正确鉴定出30个脓肿菌株的全基因组测序所证实的抗性基因型。这些结果表明，GenSeizer是检测主要致病性分枝杆菌种类的有效，可靠的平台。